AstraZeneca's Covid-19 Vaccine Saga Continues With A New Analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): GATLIN, ALLISON (AUTHOR)
  • Source:
    Investors Business Daily. 3/25/2021, pN.PAG-N.PAG. 1p.
  • Additional Information
    • Subject Terms:
      ASTRAZENECA PLC; COVID-19 vaccines; VIRAL mutation; COVID-19; STOCK exchanges
    • Abstract:
      The new results come two days after U.S. health officials expressed concern AstraZeneca (AZN) may have included "outdated" information in its interim analysis. AstraZeneca stock inched higher Thursday after the company said its coronavirus vaccine was 76% effective in a primary analysis of its U.S. final-phase test. [Extracted from the article]
    • Abstract:
      Copyright of Investors Business Daily is the property of Investor's Business Daily and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)